Supplementary Material for: Objective response and progression free survival contribute to prolong overall survival in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma.

Kazuto Tajiri (Contributor)
Kenichiro Tsukada (Contributor)
Yoshiharu Tokimitsu (Contributor)
Yuchi Motofuji (Contributor)
Kengo Kawai (Contributor)
Nozomu Muraishi (Contributor)
Aiko Murayama (Contributor)
Yuka Hayashi (Contributor)
Y. Shimizu (Contributor)
Ichiro Yasuda (Contributor)

Internal Medicine （3）

Dataset

1 Article

1 results

Filter

2024
Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
Tajiri, K., Tsukada, K., Tokimitsu, Y., Motofuji, Y., Kawai, K., Muraishi, N., Murayama, A., Hayashi, Y., Shimizu, Y. & Yasuda, I., 2024/02/01, In: Oncology (Switzerland). 102, 2, p. 131-140 10 p.
Research output: Contribution to journal › Article › peer-review
2 Scopus citations